Subscribe To

Price Alert Latest News Economic Calendar News

APTO / Aptose Biosciences Continues To Drift Without Thesis-Changing Data

Aptose has made some progress in the clinic this year, including additional complete responses for lead program HM43239 and a new formulation of luxeptinib. Expansion studies of '239 in 2023 could pave the way toward registration studies, and dose escalation studies of the new luxeptinib formulation could begin in early 2023. Read More

Demo Live Account See Partner Details

Content Topics

Aptose

Biosciences

Continues

Drift

Without

Thesis

Changing

Thesis changing

Stock

APTO

Posted: Jul 19 2022, 18:31

Author Name: Seeking Alpha

APTO News

By GlobeNewsWire
October 26, 2023

Aptose to Report Third Quarter 2023 Financial Results and Hold Conference Call on Thursday, November 9, 2023

SAN DIEGO and TORONTO, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company

By GlobeNewsWire
August 24, 2023

Aptose to Present at the H.C. Wainwright 25th Annual Global Investment Conference

SAN DIEGO and TORONTO, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clin

By Seeking Alpha
August 10, 2023

Aptose Biosciences Inc. (APTO) Q2 2023 Earnings Call Transcript

Aptose Biosciences Inc. (NASDAQ:APTO ) Q2 2023 Earnings Conference Call August 10, 2023 5:00 PM ET Company Participants Susan Pietropaolo - Corporate

By Seeking Alpha
May 8, 2023

Aptose Biosciences Inc. (APTO) Q1 2023 Earnings Call Transcript

Aptose Biosciences Inc. (NASDAQ:APTO ) Q1 2023 Earnings Conference Call May 8, 2023 5:00 PM ET Company Participants Susan Pietropaolo – Corporate Co

By GlobeNewsWire
April 10, 2023

Aptose to Participate in Canaccord Genuity's 2023 Horizons in Oncology Virtual Conference

SAN DIEGO and TORONTO, April 10, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a cli

By Pulse2
March 24, 2023

Aptose Biosciences Announces Q4 And FY 2022 Results

Aptose Biosciences (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to tr

By Seeking Alpha
March 23, 2023

Aptose Biosciences Inc. (APTO) Q4 2022 Earnings Call Transcript

Aptose Biosciences Inc. (NASDAQ:APTO ) Q4 2022 Earnings Conference Call March 23, 2023 5:00 PM ET Company Participants Susan Pietropaolo - Managing Di

By GlobeNewsWire
March 9, 2023

Aptose to Report Fourth Quarter and Full Year 2022 Financial Results and Hold Conference Call on Thursday, March 23, 2023

SAN DIEGO and TORONTO, March 09, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology compan

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.